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Available online 3 August 2016Over the past two decades, improved diagnosis, pharmaceuti-
cal therapies, and interventional strategies have impressively
improved the armamentarium of modern cardiologists in the
fight against the most incident and lethal diseases: heart fail-
ure, ischemic heart disease, and arrhythmia. The innovations
in the field have mostly been enabled by inventions based on
hypothesis-driven approaches. The invention and development
of key cardiac biomarkers, such as natriuretic peptides and
cardiac-specific troponins, may serve as examples. Based on
few candidate molecules, the discovery of these markers
requires neither high-throughput molecular screening, nor
advanced computational methodologies for interpretation
and refinement of results.
What has changed such that authors of this Special Issue on
Computational Cardiology propose the requirement of a struc-
tured interaction of clinical, molecular, and bioinformatics
experts? Evidence-based changes that have been implemented
into current guidelines of cardiovascular medicine are mostly
due to large-scale randomized clinical trials. Although this
approach was hugely successful to improve prognosis of
patients, in the future the treatment and outcome net-benefitexpected from additional or refined treatments are predicted
to become smaller and smaller. To further improve the man-
agement of heart disease, it is therefore important to increase
personalization of new approaches. While the intricate power
of statistics in randomized trials is obvious, the less than hand-
ful selection and phenotyping criteria (e.g., age, body mass
index, and kidney function) in such trials rather neglect the
individuality of patients and their diseases. Hence, it is pivotal
to enhance the characterization of prevalent and incident car-
diovascular diseases, and either better select the appropriate
therapy for the individual patient or define the personal drug
target in a single patient.
One could list the selected foreseen challenges and roles of
computational cardiology including:
 the identification of novel biomarkers with unambiguous
information on diseases;
 the prediction of outcome (intraprocedural and postproce-
dural) for existing and upcoming pharmacotherapies and
cardiac interventions;
 a real-time approach for data integration in the hospital
setting and usage of big data on a population level;
 prevention of disease by early identification of health
hazards;
 endorsement of health economic approaches in high-burden
diseases, such as heart failure;
 improvement of point of care phenotyping and decentral-
ized patient care to relieve the hospital setting;nces and
178 Genomics Proteomics Bioinformatics 14 (2016) 177–178 definition of new or personal drug-targets, e.g., that are
suited for gene repair;
 automated monitoring of novel treatments for the early
detection of treatment success and side effects.
Based on these fields of future innovations, the vision of the
future of precision medicine demands for far more than rocket
science, namely the simulation of molecular pathways, cells,
tissues, organs, and whole organisms. The ignition will be set
by advances in molecular and clinical phenotyping in conjunc-
tion with the recent developments in bioinformatics methods
for integration of multi-level high-throughput and high-
content datasets with clinical data. This will pave the way
for integrative approaches for patient care in the real sense
of personalized medicine.
In this Special Issue on Computational Cardiology, we
cover some of the exciting insights into new approaches
toward a more personalized patient care using computational
means. The authors highlight the importance of biobanks
and comprehensive data resources, building the basis for
future developments of diagnostics and potentially more tar-
geted therapies [1,2] and discuss the impact of quality control
in next-generation sequencing data [3]. Beyond DNA-based
approaches, they underline the relevance of transcriptomics,
including gene expression, circular RNAs, and microRNAs
[4–6]. In a Research Highlight, the potential of protein-coding
sequences in the non-coding transcriptome is discussed [7].
Finally, more complex data integration approaches are
described [8], leading to the whole-heart simulation of diastolic
dysfunction and heart failure [9].
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